Soft MEK Inhibitors for Localized Dermal Treatment

The patent applies local quality by designing MEK inhibitors with specific physical and chemical properties that enable selective accumulation in dermal neurofibromas. The compounds are engineered to have appropriate lipophilicity, molecular size, and transport characteristics that favor their penetration into and retention within the dermal layers and neurofibroma tissue, while limiting systemic distribution. This localized accumulation achieves effective MEK inhibition in the target tissue with reduced systemic exposure and toxicity.

The patent extracts the harmful systemic circulation component from the MEK inhibition mechanism by designing compounds that bypass oral systemic delivery. The MEK inhibitors are formulated for direct dermal application or localized delivery methods, extracting the therapeutic MEK inhibition function from the harmful systemic circulation pathway. This allows MEK inhibition to be achieved through localized tissue accumulation rather than systemic distribution, eliminating dose-limiting side effects associated with oral administration.

The patent applies parameter changes by modifying the pharmacokinetic parameters of MEK inhibitors through structural optimization. The compounds are designed with specific logP values, molecular weights, and transport properties that enable effective tissue accumulation at lower systemic doses. By changing these physical and chemical parameters, the patent achieves sufficient MEK inhibition efficacy without requiring high-dose administration, thereby reducing adverse effects while maintaining therapeutic effectiveness.